Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 7:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Dan Zandberg Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

NCT04074967
View directory record Official record
Conditions
Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab, Phase II ARRY-614 + nivolumab+ipilimumab (melanoma), Phase II ARRY-614 + nivolumab+ipilimumab (RCC)
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 4, 2026, 7:22 AM EDT
Recruiting Phase 2 Interventional

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

NCT06052839
View directory record Official record
Conditions
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Interventions
Pembrolizumab, Carboplatin, Paclitaxel
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 4, 2026, 7:22 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

NCT04080804
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Nivolumab, Relatlimab, Ipilimumab
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 4, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

NCT04369937
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
IMRT (Intensity Modulated Radiotherapy), Pembrolizumab, Cisplatin, ISA101b
Radiation · Drug · Biological
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 4, 2026, 7:22 AM EDT
Recruiting Phase 2 Interventional

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

NCT04114136
View directory record Official record
Conditions
Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
Interventions
Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 4, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

NCT04326257
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab+Relatlimab, Nivolumab+Ipilimumab
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 4, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

NCT02289209
View directory record Official record
Conditions
Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck
Interventions
Reirradiation, MK-3475
Radiation · Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
4
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 4, 2026, 7:22 AM EDT
Completed Phase 3 Interventional

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

NCT04157985
View directory record Official record
Conditions
Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
Interventions
Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
Drug · Other
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 4, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer

NCT02777385
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Pembrolizumab, Cisplatin, IMRT
Drug · Radiation
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 4, 2026, 7:22 AM EDT